Immutep (IMMP) Investors Alerted by Faruqi & Faruqi on Class Action Deadline Approaching in 2026

Attention Immutep Investors

Faruqi & Faruqi, LLP, a prominent national law firm specializing in securities, is currently investigating potential legal claims against Immutep Limited (NASDAQ: IMMP). The firm is reminding investors of the approaching deadline to join a federal securities class action, which is set for July 6, 2026.

This lawsuit is mainly directed at investors who acquired securities in Immutep between March 24, 2025, and March 12, 2026. Those who experienced losses during this period are encouraged to reach out to the firm to understand their legal rights and options. James (Josh) Wilson, a partner at Faruqi & Faruqi, is leading the charge on this case and can be contacted directly for more information.

Background on Immutep's Clinical Trials

The crux of the investigation centers around the allegations that Immutep and its executives breached federal securities regulations by issuing false or misleading statements concerning the outcomes of their TACTI-004 Phase III clinical trial study for the drug eftilagimod alfa. Prior to significant developments in the case, Immutep had boasted about strong operational progress and positive results from earlier trials, TACTI-002 and INSIGHT-003.However, internal communications suggest that the company was aware of the risks surrounding the trial’s efficacy.

On March 13, 2026, Immutep released a press statement announcing the recommendation from the Independent Data Monitoring Committee (IDMC) to discontinue the TACTI-004 trial due to findings from an interim futility analysis. This led to a dramatic plunge in Immutep's stock price, with a staggering drop of 82.6%, closing at $0.48 per share. This drastic fall not only signals potential mismanagement but also raises questions about the transparency and communication from Immutep's leadership.

Legal Implications for Investors

Investors must note that becoming a lead plaintiff in this class action carries its benefits. The lead plaintiff is generally recognized as having the largest financial interest and plays a crucial role in overseeing the litigation. However, participation as a lead plaintiff or remaining an absent class member will not affect your eligibility for any recovery potentially awarded through the class action.

Faruqi & Faruqi also invites anyone possessing information related to Immutep’s conduct during this troublesome period—such as former employees or whistleblowers—to come forward and assist in fabricating a stronger case against the company.

How to Proceed

For more information about the class action against Immutep Limited, individuals can visit Faruqi & Faruqi's website or call their legal team for a direct consultation. This is a pivotal time for investors who have suffered losses; timely action can lead to crucial support in navigating this increasingly complicated legal scenario.

Stay informed and proactive; the deadline for filing claims is coming up soon, and investors should not miss the chance to protect their rights and potential recoveries.